Monopar Therapeutics Inc.
MNPR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $13 | $6 | $8 | $6 |
| G&A Expenses | $3 | $3 | $3 | $3 |
| SG&A Expenses | $3 | $3 | $3 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $16 | $9 | $11 | $9 |
| Operating Income | -$16 | -$9 | -$11 | -$9 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $0 | $0 | $0 |
| Pre-Tax Income | -$16 | -$8 | -$11 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$16 | -$8 | -$11 | -$9 |
| % Margin | – | – | – | – |
| EPS | -1.36 | -0.58 | -0.83 | -0.73 |
| % Growth | -134.5% | 30.1% | -13.7% | – |
| EPS Diluted | -1.36 | -0.58 | -0.83 | -0.73 |
| Weighted Avg Shares Out | 11 | 15 | 13 | 12 |
| Weighted Avg Shares Out Dil | 11 | 15 | 13 | 12 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$16 | -$9 | -$11 | -$9 |
| % Margin | – | – | – | – |